A Study of Axitinib, a VEGF Receptor Tyrosine Kinase Inhibitor, in Children and Adolescents With Recurrent or Refractory Solid Tumors: A Children’s Oncology Group Phase 1 and Pilot Consortium Trial (ADVL1315)
Cancer - United States
doi 10.1002/cncr.31725
Full Text
Open PDFAbstract
Available in full text
Date
November 5, 2018
Authors
Publisher
Wiley